Aria CV

Executive Summary

Aria CV is a privately held medical device company developing a novel, implantable device for the treatment of Pulmonary Arterial Hypertension (PAH). Founded in 2010 and headquartered in St. Paul, Minnesota, the company's technology is a passive, motion-driven system designed to restore compliance to the pulmonary artery without batteries, pumps, or electronics. By reducing the workload on the right side of the heart, the device aims to improve patient outcomes and quality of life. PAH is a rare, progressive condition with limited treatment options, and Aria CV's device addresses an unmet need for mechanical intervention that may complement or replace pharmacological therapies. The company is currently in clinical development, with early studies suggesting safety and efficacy. While specific financial details and stage are undisclosed, Aria CV has likely advanced through initial feasibility trials and may be approaching pivotal study enrollment or regulatory submission. If successful, the device could become a first-in-class therapy for PAH, potentially attracting interest from larger cardiovascular players. The company's progress is closely watched by investors and clinicians, given the significant morbidity associated with PAH. Near-term catalysts include updates from clinical trials, potential FDA interactions, and financing events to support commercialization.

Upcoming Catalysts (preview)

• H2 2026Pivotal Trial Enrollment Completion or Interim Data Readout55% success
• 2027FDA Submission for Premarket Approval (PMA)40% success
• Q4 2026Series C or D Financing Round to Fund Commercialization70% success